Degradation-resistant mononucleoside phosphate compounds

Details Degradation-resistant mononucleoside phosphate compounds Degradation-resistant mononucleoside phosphate compounds

2005-11-21

2008-10-14

Lewis, Patrick T (Department: 1623)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C514S043000, C514S046000, C514S047000, C514S048000

Reexamination Certificate

active

07435724

ABSTRACT:
The present invention relates to mononucleoside phosphate compounds that have the benefits of a dinucleotide pharmaceutical. These mononucleoside phosphates can be made from a mononucleotide that has been modified by attaching a degradation-resistant substituent on the terminal phosphate of a polyphosphate mononucleotide. By attaching this degradation-resistant substituent, the stability from degradation matches or exceeds those of certain dinucleotides. The mononucleoside phosphate compounds of the present invention are useful in preventing and treating epithelial tissue diseases or diseases or disorders associated with platelet aggregation.

REFERENCES:
patent: 3321463 (1967-05-01), Moffatt et al.
patent: 5292498 (1994-03-01), Boucher, Jr.
patent: 5628984 (1997-05-01), Boucher, Jr.
patent: 5635160 (1997-06-01), Stutts, III et al.
patent: 5654285 (1997-08-01), Ingall et al.
patent: 5721219 (1998-02-01), Ingall et al.
patent: 5747496 (1998-05-01), Cox et al.
patent: 5837861 (1998-11-01), Pendergast et al.
patent: 5900407 (1999-05-01), Yerxa et al.
patent: 5955447 (1999-09-01), Ingall et al.
patent: 6166022 (2000-12-01), Brown et al.
patent: 6319908 (2001-11-01), Yerxa et al.
patent: 6323187 (2001-11-01), Yerxa et al.
patent: WO 92/17488 (1992-10-01), None
patent: WO 94/18216 (1994-08-01), None
patent: WO 97/03084 (1997-01-01), None
patent: WO 98/28300 (1998-07-01), None
patent: WO 00/33080 (2000-06-01), None
patent: WO 00/34283 (2000-06-01), None
patent: WO 01/19826 (2001-03-01), None
patent: WO 01/36421 (2001-05-01), None
patent: WO 01/39781 (2001-06-01), None
Abbracchio and Burnstock, “Purinergic Signalling: Pathophysiological Roles,”Jpn J. Pharmacol, 78:113-45 (1998).
Brown, et al., “Evidence that UTP and ATP Regulate Phosphollpase C through a Common Extracellular 5′ -Nucleotide Receptor in Human Airway Epithelial Cells,”Mol. Pharmocol.40:648-55 (1991).
Drutz, et al., “Uridine 5′ Triphosphate (UTP) Regulates Mucocillary Clearance via Purinergic Receptor Activation,”Drug Dev. Res.37(3):185 (1996).
Gobran, “P2u purinoceptor stimulation of surfactant secretion coupled to phosphatidylcholine hydrolysis in type II cells,”Am. J. Physiol.267:L625-L633 (1994).
Moffatt et al., “Nucleoside polyphosphates . . . ”, Journal of the American Chemical Society 80, 3756-61, 1958.
Yerxa, et al.,Durgs of the Future, 24:759-769 (1999).

Affiliated with

Also associated with

Rating

Degradation-resistant mononucleoside phosphate compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Degradation-resistant mononucleoside phosphate compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Degradation-resistant mononucleoside phosphate compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4013789